University of Saskatchewan

usask.ca

Total trials

238

Active

24

Phase 3

17

Total enrollment

22,994

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ketamine3
Tiotropium2
Indomethacin 50 MG1
IV iron1
50 mg 89Zr-DFO-Nimotuzumab1
1 mg 89Zr-DFO-Nimotuzumab1
IRE plus checkpoint inhibitor1
IRE plus Checkpoint Inhibitor plus CpG-ODN1
NeuroEPO1
IRDye800CW-nimotuzumab1
FOLFOXIRI and Bevacizumab1
Cannabidiol1

Next readouts

  • 2024-12-31
  • 2025-11
  • 2025-12-31
  • 2026-09
  • 2026-09
  • 2026-12-31
  • 2027-01
  • 2027-12
  • 2028-12-01
  • 2030-03

Top conditions

  • Asthma20
  • Osteoporosis10
  • Sarcopenia7
  • Pain7
  • Coronary Artery Disease6
  • Depression5
  • Anesthesia4
  • Ketamine4

Frequently asked questions about University of Saskatchewan

How many clinical trials does University of Saskatchewan have on ClinicalTrials.gov?
University of Saskatchewan is listed as the lead sponsor on 238 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Saskatchewan's trials are in Phase 3?
17 of University of Saskatchewan's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does University of Saskatchewan focus on?
University of Saskatchewan's most-studied conditions on ClinicalTrials.gov are Asthma, Osteoporosis, Sarcopenia, Pain, Coronary Artery Disease.
When are University of Saskatchewan's next clinical trial readouts?
University of Saskatchewan has 10 upcoming primary-completion readouts tracked here; the soonest is “Three Dimensional Ultrasonographic Detection of Human Ovulation”, expected around 2024-12-31.